gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

CD79b molecule, immunoglobulin-associated beta

B29, CD79b, Igbeta, Igb
The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: BCR, CAN, IgM, CD5, CD19
Papers on B29
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biologic heterogeneity of the disease.
Shipp et al., Boston, United States. In Blood, Feb 2016
Six of the eight DLBCL models were ABC-type tumors that exhibited ABC-associated mutations such as MYD88, CD79B, CARD11 and PIM1.
Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Yoshino et al., Isehara, Japan. In Am J Surg Pathol, Feb 2016
ABC-like DLBCL was reported to have gain-of-function mutations in MYD88, CD79B, CARD11, and TNFAIP3, resulting in constitutive activation of the NFκB pathway.
CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
Park et al., Seoul, South Korea. In Leuk Lymphoma, Jan 2016
In the current study, cDNA microarray and Western blot analyses revealed CD79B upregulation in the activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) that display differential resistance to ibrutinib.
Genetic landscapes of relapsed and refractory diffuse large B cell lymphomas.
Johnson et al., Vancouver, Canada. In Clin Cancer Res, Jan 2016
We detected mutations that may be affect sensitivity to novel therapeutics, such as MYD88 and CD79B mutations, in 31% and 23% of patients with activated B cell-type of rrDLBCL, respectively.
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study.
Ghia et al., Milano, Italy. In Leukemia, Jan 2016
CD19, CD20, CD5, CD43, CD79b, and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood.
Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Forero-Torres et al., Birmingham, United States. In Curr Oncol Rep, Sep 2015
Newer ADCs, such as polatuzumab vedotin (targeting CD79b), pinatuzumab vedotin (targeting CD22), inotuzumab ozogamicin (targeting CD19), SAR3419 (targeting CD19), IMGN529 (targeting CD37), and SGN-CD19A (targeting CD19), have shown promising preclinical and early clinical activity.
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Morschhauser et al., Seattle, United States. In Lancet Oncol, Jun 2015
Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the safety and clinical activity of polatuzumab vedotin in relapsed or refractory B-cell NHL and chronic lymphocytic leukaemia (CLL).
Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.
Watanabe et al., Tokyo, Japan. In Sci Rep, 2014
Conventional screening and RISC profiling identify multiple targets (CD79B, SYK, PKCβII, PLCγ1, IKKβ, NIK, MYD88, PI3K class I (α/β/δ/γ), RasGRP3); signaling network habitually faces interference composed by miRNA group in normal B cells.
Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
Siebert et al., Köln, Germany. In Acta Neuropathol, 2014
Several important pathways, i.e., the B cell receptor (BCR), the toll-like receptor, and the nuclear factor-κB pathway, are activated frequently due to genetic changes affecting genes like CD79B, SHIP, CBL, BLNK, CARD11, MALT1, BCL2, and MYD88.
B-cell receptor signaling as a driver of lymphoma development and evolution.
Wiestner et al., Bethesda, United States. In Semin Cancer Biol, 2013
In a number of B-cell malignancies, activating mutations in signal transduction components of the BCR pathway have been identified; prominent examples are activated B-cell-like (ABC) diffuse large B-cell lymphomas (DLBCL) that carry mutations in CD79B and CARD11 and display chronic active BCR signaling resulting in constitutive activation of the NF-κB pathway.
Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.
Cambier et al., Denver, United States. In Immunity, 2011
Anergic B cells are characterized by impaired signaling and activation after aggregation of their antigen receptors (BCR).
Endocytosed BCRs sequentially regulate MAPK and Akt signaling pathways from intracellular compartments.
Pierce et al., Rockville, United States. In Nat Immunol, 2011
endocytosed BCR sequentially regulates MAPK and Akt signaling pathways from intracellular compartments
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Stegmeier et al., Cambridge, United States. In Cancer Res, 2011
STN produced significant antitumor effects in a mouse xenograft model of CD79A/B-mutated DLBCL.
Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma: a possible post transcriptional regulation.
Yoshino et al., Okayama, Japan. In Pathol Int, 2011
Expression of CD79b is downregulated in both plasma cells and plasma cell myeloma.
The role of Ig-α/β in B cell antigen receptor internalization.
Matsuuchi et al., Vancouver, Canada. In Immunol Lett, 2010
Data indicate that both the Igalpha and the Igbeta cytoplasmic domains alone are sufficient for trafficking to lysosomal compartments, and are unaffected by mutation of 4 amino acid residues within their respective ITAMs.
The membrane skeleton controls diffusion dynamics and signaling through the B cell receptor.
Batista et al., London, United Kingdom. In Immunity, 2010
We identified the intracellular domain of Igbeta as important in mediating this restriction in diffusion.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Staudt et al., Bethesda, United States. In Nature, 2010
In addition, knockdown of proximal BCR subunits (IgM, Ig-kappa, CD79A and CD79B) killed ABC DLBCLs with wild-type CARD11 but not other lymphomas.
Spontaneous mutation in the Cd79b gene leads to a block in B-lymphocyte development at the C' (early pre-B) stage.
Matzinger et al., Bethesda, United States. In Genes Immun, 2009
describe a novel mouse with a spontaneous mutation in the Cd79b gene leading to a block in B-cell development and agammaglobulinemia.
Primary B cell immunodeficiencies: comparisons and contrasts.
Campana et al., Memphis, United States. In Annu Rev Immunol, 2008
Mutations in Btk, components of the pre-B cell and B cell receptor (lambda5, Igalpha, Igbeta), or the scaffold protein BLNK account for approximately 90% of patients with defects in early B cell development.
Ig beta deficiency in humans.
Plebani et al., Brescia, Italy. In Curr Opin Allergy Clin Immunol, 2008
mutations responsible for agammaglobulinemia in humans
share on facebooktweetadd +1mail to friends